Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcoidosis and Systemic Comorbidities: Sex-Related Differences in a Multicenter Italian Cohort.

Respiration; international review of thoracic diseases·2026
Same author

Prevalence, Clinical and Functional Determinants of Chronic Hypoxemia and Respiratory Failure in Patients with Stable COPD.

Journal of clinical medicine·2026
Same author

Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG·2026
Same author

Should triple inhaled therapy be initiated earlier in the disease course of COPD to modify long-term outcomes, including mortality, exacerbations, and cardiovascular risk?

Respiratory medicine·2026
Same author

Pulmonary and cerebral damage in COVID-19 survivors: is there any association?

Annals of medicine·2026
Same author

Use of an Anti-Thymic Stromal Lymphopoietin Agent in Patients With Asthma and Clinically Significant Bronchiectasis: A Case Series.

Chest·2026

Related Experiment Video

Updated: May 25, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Tiotropium: what came after the UPLIFT study.

Pierachille Santus1, Fabiano Di Marco, Dejan Radovanovic

  • 1Università degli Studi di Milano, Pneumologia Riabilitativa - Fondazione Salvatore Maugeri, Istituto Scientifico di Riabilitazione di Milano (IRCCS), Via Camaldoli, 64, 20152 Milano, Italy. Pierachille.santus@unimi.it

Expert Opinion on Pharmacotherapy
|January 31, 2012
PubMed
Summary
This summary is machine-generated.

Tiotropium effectively treats chronic obstructive pulmonary disease (COPD) by reducing airflow obstruction and lung hyperinflation. New data confirm its efficacy, with Respimat device showing comparable results to HandiHaler.

Related Experiment Videos

Last Updated: May 25, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) involves progressive bronchial obstruction.
  • Bronchodilators are the standard maintenance therapy for COPD.
  • Tiotropium is a safe and effective anticholinergic bronchodilator.

Purpose of the Study:

  • To review the efficacy of tiotropium for COPD maintenance therapy.
  • To evaluate tiotropium administration via the Respimat device.

Main Methods:

  • Systematic review of clinical trials and meta-analyses.
  • Literature search focused on studies published after the UPLIFT study.
  • Primary endpoint focused on tiotropium efficacy.

Main Results:

  • Post-UPLIFT data confirm tiotropium's efficacy in COPD maintenance.
  • Tiotropium reduces airflow obstruction and lung hyperinflation.
  • Respimat device demonstrates comparable efficacy to HandiHaler with bioequivalent doses.

Conclusions:

  • Tiotropium remains a key therapy for COPD.
  • Further standardization in evaluating COPD exacerbations and outcomes is needed.
  • Respimat offers a comparable alternative for tiotropium delivery.